Precinct Partner: Vaxxas
Vaxxas unveiled its new headquarters and manufacturing facility at Northshore Brisbane in June 2023. The facility enables Vaxxas to produce clinical samples of its ground-breaking needle-free vaccine patch technology on-site, with the potential to scale up for future commercial production.
Vaxxas’ needle-free device uses a small patch with its surface covered with thousands of microprojections, coated with a vaccine. When applied to the skin, it targets the immune cells that are abundant just below the skin, offering a more efficient and less invasive method than traditional injections. The technology also reduces waste by removing the need for the substantial protective packaging and equipment required for traditional needles and syringes.
The collaboration between Economic Development Queensland (EDQ) and Vaxxas is helping to retain and develop skills locally, contributing to the advancement of Queensland’s biotech industry. The innovative work of Vaxxas has already garnered significant attention from global partners, governments, pharmaceutical companies, and philanthropic organisations, including the World Health Organisation, CEPI, Welcome Trust, and the Bill and Melinda Gates Foundation.
This symbiotic partnership between Northshore Brisbane and Vaxxas demonstrates the unique solutions available to support the local economy, and foster innovation and progress.
